Forty Seven, Inc. Announces Initial Data from Its Phase 1B Clinical Trial Evaluating 5F9 as Monotherapy and in Combination with Azacitidine for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome

Forty Seven, Inc. announced that promising initial data from its Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) will be presented in a poster discussion session at the 2019 ASCO Annual Meeting. Forty Seven’s Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of AML and MDS is funded in part by a research grant awarded by the California Institute for Regenerative Medicine (CIRM).